The increase in research and development expenses was primarily due to expenses associated with clinical research and trials, primarily related to RENEW and support of our BLA efforts. Operating loss for the Q2 was $13,900,000 compared to operating income of $9,700,000 last year, a decrease of 23,600,000 Excluding non cash impairment charges, write downs, restructuring and amortization expenses in both periods, our non GAAP operating income was $9,700,000 or 7.5 percent of sales compared to $10,800,000 or 9.2 percent of sales last year. Net loss for the Q2 was $17,000,000 compared to net income of $5,300,000 last year, a decrease of $22,400,000 Adjusted net income for the Q2 was $200,000 compared to $6,100,000 last year, a decrease in adjusted net loss of 5,900,000 As a reminder, adjusted net income is defined as GAAP net income, adjusted to exclude the effect of amortization, restructuring charges, write downs, capitalized software costs and impairment of building and improvements and resulting income taxes on these items. Adjusted EBITDA for the Q2 was $15,600,000 or 12 percent of net revenue compared to $15,400,000 or 13 percent of net revenue last year. We've provided a full reconciliation of our adjusted net income and adjusted EBITDA results in our earnings press release.